Doconexent

Generic Name: Doconexent

Brand Names: Animi-3 With Vitamin D, Citranatal Harmony

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₃₂O_₂

CAS Number: 6217-54-5

Unique Ingredient Identifier: ZAD9OKH9JC

Background: A mixture of fish oil and primrose oil, doconexent is used as a high-docosahexaenoic acid (DHA) supplement. DHA is a 22 carbon chain with 6 cis double bonds with anti-inflammatory effects. It can be biosythesized from alpha-linolenic acid or commercially manufactured from microalgae. It is an omega-3 fatty acid and primary structural component of the human b...

Indication: Used as a high-docosahexaenoic acid (DHA) oral supplement.

Associated Conditions: Fredrickson classification type IV Hyperlipidemia, Fredrickson type IIb hyperlipidemia, Type III hyperlipidaemia

Associated Therapies: Nutritional supplementation

Clinical Trials

Differential Thrombogenesis by EPA and DHA Mediated by HDL

Early Phase 1

Not yet recruiting

Conditions: Lipid Metabolism Disorders

Interventions: Drug: DHA
Drug: EPA

First Posted Date: 2024-07-10

Last Posted Date: 2024-12-17

Lead Sponsor: The Miriam Hospital

Target Recruit Count: 80

Registration Number: NCT06494488

Docosahexaenoic Acid on Breath Holding Spells in Children

Phase 3

Recruiting

Conditions: Breath Holding Attack

Interventions: Drug: Placebo
Drug: DHA

First Posted Date: 2019-05-29

Last Posted Date: 2019-05-29

Lead Sponsor: Sherief Abd-Elsalam

Target Recruit Count: 60

Registration Number: NCT03965988

Locations: 🇪🇬
Sherief Abd-Elsalam, Tanta, Egypt

DHA Brain Delivery Trial

Phase 2

Completed

Conditions: Brain DHA Delivery and Alzheimer's Disease Risk

Interventions: Drug: Placebo
Drug: DHA

First Posted Date: 2018-08-03

Last Posted Date: 2024-06-07

Lead Sponsor: University of Southern California

Target Recruit Count: 365

Registration Number: NCT03613844

Locations: 🇺🇸
USC Keck School of Medicine, Los Angeles, California, United States

Docosahexaenoic Acid (DHA) Supplementation in Amblyopia

Phase 1

Withdrawn

Conditions: Amblyopia

Interventions: Drug: Placebo Oral Tablet
Drug: Docosahexaenoic Acid

First Posted Date: 2018-01-18

Last Posted Date: 2024-02-09

Lead Sponsor: Johns Hopkins University

Registration Number: NCT03402789

Locations: 🇺🇸
Johns Hopkins Hospital, Wilmer Eye Institute, Baltimore, Maryland, United States

Dose-Finding Study of SC411 in Children With Sickle Cell Disease

Phase 2

Conditions: Sickle Cell Disease

Interventions: Drug: Docosahexaenoic Acid
Drug: Placebo

First Posted Date: 2016-11-25

Last Posted Date: 2019-01-31

Lead Sponsor: Micelle BioPharma Inc

Target Recruit Count: 68

Registration Number: NCT02973360

Locations: 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
Children's Healthcare of Atlanta - Emory University, Atlanta, Georgia, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States

and more 8 locations

Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF)

Phase 2

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Docosahexaenoic acid
Drug: Sunflower Oil

First Posted Date: 2016-02-24

Last Posted Date: 2019-05-28

Lead Sponsor: Hospices Civils de Lyon

Target Recruit Count: 10

Registration Number: NCT02690857

Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy

Early Phase 1

Completed

Conditions: Cognitive Dysfunction

Interventions: Drug: DHA
Drug: Placebo

First Posted Date: 2015-08-07

Last Posted Date: 2022-01-24

Lead Sponsor: Carol Fabian, MD

Target Recruit Count: 24

Registration Number: NCT02517502

Locations: 🇺🇸
Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

Kansas University DHA Outcome Study (KUDOS) Follow-Up

Phase 3

Completed

Conditions: Pregnancy

Interventions: Drug: Placebo Capsule
Drug: DHA

First Posted Date: 2015-07-01

Last Posted Date: 2018-02-07

Lead Sponsor: Susan Carlson, PhD

Target Recruit Count: 190

Registration Number: NCT02487771

Locations: 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

The Effects of DHA on Periodontitis

Phase 2

Completed

Conditions: Gingivitis
Inflammation
Periodontitis

Interventions: Drug: Aspirin
Drug: Placebo (for Docosahexaenoic acid)
Drug: Docosahexaenoic acid

First Posted Date: 2013-11-06

Last Posted Date: 2017-12-13

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 55

Registration Number: NCT01976806

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

Phase 2

Completed

Conditions: Stage IIIC Breast Cancer
Ductal Breast Carcinoma In Situ
Stage IIB Breast Cancer
Stage IIIA Breast Cancer
Benign Breast Neoplasm
Invasive Breast Carcinoma
Lobular Breast Carcinoma In Situ
Paget Disease of the Breast
Stage IA Breast Cancer
Stage IB Breast Cancer

Interventions: Drug: Docosahexaenoic Acid
Other: Placebo

First Posted Date: 2013-05-08

Last Posted Date: 2021-12-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 65

Registration Number: NCT01849250

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy